Schedule 1 - Healthcare Investment Opportunities

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

COMPANY NAME:

Healthcare Investment Opportunities plc (to be renamed Collagen Solutions plc) ("the Company")

COMPANY REGISTERED OFFICE ADDRESSAND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :

Registered address:

1 Scott Place, 2 Hardman Street, Manchester, M3 3AA

Trading address:

3 Robroyston Oval, Nova Technology Park, Glasgow, G33 1AP

COUNTRY OF INCORPORATION:

England & Wales

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

http://www.healthcareinvestmentopps.co.uk

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

Healthcare Investment Opportunities was established as an Investment Company under the leadership of David Evans with the objective of generating an attractive rate of return for Shareholders predominantly through capital appreciation by acquiring and/or investing in businesses in the healthcare sector. The Company's primary investment focus has been businesses that have embedded or protected IP, are scalable and have the potential to gain significant market share.

Subject to shareholder approval, the Company has agreed to purchase Collbio Limited ("Collbio"). Collbio manufactures medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics.

Collbio has entered into an agreement to acquire, conditional upon Admission, the assets and business of Collagen Solutions LLC, based in San Jose, California. Collagen Solutions provides medical grade bovine collagen, corium and tendon from closed herd and GBR1 countries and customised collagen based on customer requirements. Collagen Solutions also offers research and development services to create devices from concept to clinical trial stage which includes consultancy services for technology transfers to outside contract manufacturing facilities.

Admission is sought as a result of a reverse takeover under Rule 14 of the AIM Rules for Companies.

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

63,826,007 Ordinary Shares of £0.01 each at an issue price of 12.5p.

No restrictions as to transfer of the securities.

CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) ANDANTICIPATED MARKET CAPITALISATION ON ADMISSION:

Anticipated market capitalisation on Admission: £8 million

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

30.23%

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORMTO WHICH THE AIM COMPANY HAS APPLIED OR AGREED TO HAVE ANY OF ITS SECURITIES (INCLUDING ITS AIM SECURITIES) ADMITTED OR TRADED:

N/A

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS(underlining the first name by which each is known or including any other name by which each is known):

David Eric Evans (Non-Executive Chairman)

Kevin William Wilson (Non-Executive Director)

Malcolm John Gillies (Non-Executive Director)

Stewart White (Chief Executive)

FULL NAMESAND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL,BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

N/A

(i) ANTICIPATED ACCOUNTING REFERENCE DATE

(ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information)

(iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

(i) 31 March

(ii) 30 September 2013

(iii) 30 September 2014; 30 December 2014; 30 September 2015

EXPECTED ADMISSION DATE:

2 January 2014

NAME AND ADDRESS OF NOMINATED ADVISER:

Zeus Capital Ltd

23 Berkeley Square

London

W1J 6HE

3 Ralli Courts

West Riverside

Manchester

M3 5FT

NAME AND ADDRESS OF BROKER:

Zeus Capital Ltd

23 Berkeley Square

London

W1J 6HE

3 Ralli Courts

West Riverside

Manchester

M3 5FT

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENTWILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

http://www.healthcareinvestmentopps.co.uk

This website will contain full details about the Company and the admission of its ordinary shares to trading on AIM.

DATE OF NOTIFICATION:

16 December 2013

NEW/ UPDATE:

NEW